There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lantheus (LNTH – Research Report), Incyte (INCY – Research Report) and Fusion Pharmaceuticals (FUSN – Research Report) with bullish sentiments.
Lantheus (LNTH)
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Lantheus yesterday and set a price target of $96.00. The company’s shares closed last Wednesday at $56.37, close to its 52-week low of $50.20.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Lantheus has an analyst consensus of Strong Buy, with a price target consensus of $96.63.
See today’s best-performing stocks on TipRanks >>
Incyte (INCY)
In a report issued on February 13, Andrew Berens from Leerink Partners maintained a Buy rating on Incyte, with a price target of $83.00. The company’s shares closed last Wednesday at $57.89.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $73.60, which is a 25.6% upside from current levels. In a report issued on February 5, Citi also maintained a Buy rating on the stock with a $82.00 price target.
Fusion Pharmaceuticals (FUSN)
Leerink Partners analyst Faisal Khurshid maintained a Buy rating on Fusion Pharmaceuticals yesterday. The company’s shares closed last Wednesday at $11.17, close to its 52-week high of $12.24.
Khurshid has an average return of
According to TipRanks.com, Khurshid is ranked #299 out of 8716 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fusion Pharmaceuticals with a $14.75 average price target, which is a 31.9% upside from current levels. In a report issued on February 1, JonesTrading also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LNTH:
- Lantheus announces collaboration with NIA-sponsored study called CLARiTI
- Lantheus announces collaboration with a NIA-sponsored study called CLARiTT
- Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
- Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
- TipRanks’ ‘Perfect 10’ List: 2 Top-Scoring Stocks Worth Considering at Current Low Levels
